- Phase 3 trial results: mRNA-1273 vaccine continued to be safe and efficacious more than five months after second dose http://dx.doi.org/10.1056/nejmoa2113017 24 comments science
Linked pages
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2109522 1533 comments
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2101765?query=featured_home 528 comments
- Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2104983 38 comments
- https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 1 comment
- Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2205650 0 comments
- Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208375 0 comments
Related searches:
Search whole site: site:dx.doi.org
Search title: Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM
See how to search.